03 Mar 2015 Posted in News By Press Office
On 3 March, Sir Bruce Keogh, National Medical Director for NHS England; Dr Keith Ridge, the Chief Pharmaceutical Officer and Jonathan Emms, ABPI President will launch the first PPRS/Medicines Optimisation roadshow, which is being delivered as part of a joint programme of action by NHS England and the ABPI, with the Academic Health Science Networks (AHSNs), to improve patient outcomes.
The event, hosted by Imperial College Health Partners, is the first in a series of 14 events across England, organised by ABPI and NHS England in partnership with the 15 AHSNs.
The primary aim of these events is to work with local clinical, financial and operational leaders to harness the opportunity of the PPRS and accelerate the use of innovative, clinically and cost effective medicines, improving outcomes for patients. The programme is guided by the four principles of medicines optimisation that were published by the Royal Pharmaceutical Society in May 2013: to understand the patient’s experience; evidence-based choice of medicines; make medicines optimisation part of routine practice; ensure medicines use is as safe as possible.
Commenting on the launch of the series, ABPI Executive Director of Commercial, Alison Clough, said:
“Medicines optimisation has been given a huge boost by the latest PPRS which brings a new level of collaboration between the pharmaceutical industry, NHS England and other key stakeholders. The ABPI and NHS England are running a joint programme, guided by the principles of medicines optimisation, which will help NHS medical, pharmacy, operations and finance staff understand and harness the unique opportunity of the PPRS agreement and look beyond short-term cost containment measures to the long term benefit of medicines to patients.
“More broadly the 2014 PPRS aims to improve access to innovative medicines, through a payment mechanism where the pharmaceutical industry has committed to underwrite the growth in branded medicines spend. PPRS means that clinicians can prescribe the newer medicines their patients need, less constrained by cost.”
The roadshows will introduce the national context for the medicines optimisation initiative and explain the priority attached to implementation of PPRS. They will also showcase examples of local and national best practice and support AHSNs to work with all local stakeholders to develop a local medicines optimisation strategy.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811